Generic Contrast Agents – Now You Have a Choice

Visit Fresenius Kabi to learn more. Booth #3235

Fresenius Kabi has expanded their radiology portfolio to include additional cost-effective products, including the CT and MRI contrast agents featured in their booth this year at RSNA 2024.

In today’s world, having only one source of supply can be challenging. Keep your options open by expanding your choices. Diversify your options with a leading provider of generic injectable pharmaceuticals.

QR Code By partnering with Fresenius Kabi, you will have access to FDA-approved generic contrast agents that are fully substitutable to the brand-name products – at a lower cost. Now you have a choice.

Learn more about available generic contrast agents from Fresenius Kabi at GenericContrastAgents.com or scan the code to view their contrast agents product catalog.

Fresenius Kabi at a Glance

Fresenius Kabi is a global health care company that specializes in essential medicines and technologies for infusion, transfusion and clinical nutrition – with a comprehensive portfolio of injectable drugs and delivery systems used to treat a broad spectrum of patients.

We are committed to putting essential medicines and technologies in the hands of health care providers. We work together to find the best answers to the challenges faced in providing quality patient care. We leverage our 100-year history so that clinicians can deliver therapies in ways that are safe, effective and affordable.

For more information about Fresenius Kabi, visit fresenius-kabi.com/us/.

Around the web

Health Imaging

Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business

Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business

‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.